GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Lindner, M.  (3)
  • 2005-2009  (3)
Material
Publisher
Language
Years
  • 2005-2009  (3)
Year
Subjects(RVK)
  • 1
    In: Journal of Inherited Metabolic Disease, Wiley, Vol. 32, No. 4 ( 2009-08), p. 488-497
    Abstract: At present, long‐chain fatty acid oxidation (FAO) defects are diagnosed in a number of countries by newborn screening using tandem mass spectrometry. In the majority of cases #Affected newborns are asymptomatic at time of diagnosis and acute clinical presentations can be avoided by early preventive measures. Because evidence‐based studies on management of long‐chain FAO defects are lacking, we carried out a retrospective analysis of 75 patients from 18 metabolic centres in Germany, Switzerland, Austria and the Netherlands with special regard to treatment and disease outcome. Dietary treatment is effective in many patients and can prevent acute metabolic derangements and prevent or reverse severe long‐term complications such as cardiomyopathy. However, 38% of patients with very long‐chain acyl‐CoA dehydrogenase (VLCAD) deficiency had intermittent muscle weakness and pain despite adhering to therapy. Seventy‐six per cent of patients with disorders of the mitochondrial trifunctional protein (TFP)‐complex including long‐chain 3‐hydroxyacyl‐CoA dehydrogenase (LCHAD) deficiency, had long‐term myopathic symptoms. Of these, 21% had irreversible peripheral neuropathy and 43% had retinopathy. The main principle of treatment was a fat‐reduced and fat‐modified diet. Fat restriction differed among patients with different enzyme defects and was strictest in disorders of the TFP‐complex. Patients with a medium‐chain fat‐based diet received supplementation of essential long‐chain fatty acids. l‐Carnitine was supplemented in about half of the patients, but in none of the patients with VLCAD deficiency identified by newborn screening. In summary, in this cohort the treatment regimen was adapted to the severity of the underlying enzyme defect and thus differed among the group of long‐chain FAO defects.
    Type of Medium: Online Resource
    ISSN: 0141-8955 , 1573-2665
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 2006875-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Inherited Metabolic Disease, Wiley, Vol. 32, No. 4 ( 2009-08), p. 498-505
    Abstract: Published data on treatment of fatty acid oxidation defects are scarce. Treatment recommendations have been developed on the basis of observations in 75 patients with long‐chain fatty acid oxidation defects from 18 metabolic centres in Central Europe. Recommendations are based on expert practice and are suggested to be the basis for further multicentre prospective studies and the development of approved treatment guidelines. Considering that disease complications and prognosis differ between different disorders of long‐chain fatty acid oxidation and also depend on the severity of the underlying enzyme deficiency, treatment recommendations have to be disease‐specific and depend on individual disease severity. Disorders of the mitochondrial trifunctional protein are associated with the most severe clinical picture and require a strict fat‐reduced and fat‐modified (medium‐chain triglyceride‐supplemented) diet. Many patients still suffer acute life‐threatening events or long‐term neuropathic symptoms despite adequate treatment, and newborn screening has not significantly changed the prognosis for these severe phenotypes. Very long‐chain acyl‐CoA dehydrogenase deficiency recognized in neonatal screening, in contrast, frequently has a less severe disease course and dietary restrictions in many patients may be loosened. On the basis of the collected data, recommendations are given with regard to the fat and carbohydrate content of the diet, the maximal length of fasting periods and the use of l‐carnitine in long‐chain fatty acid oxidation defects.
    Type of Medium: Online Resource
    ISSN: 0141-8955 , 1573-2665
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 2006875-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Inherited Metabolic Disease, Wiley, Vol. 32, No. 4 ( 2009-08), p. 506-513
    Abstract: Background: As part of the German Collaborative Study of Children Treated for Phenylketonuria (PKU), a three‐day protein loading test was applied to children at 6 months of age. This load elicits three principal types of blood phenylalanine (Phe) response, with types I and III clinically corresponding to classic PKU and mild hyperphenylalaninaemia not requiring diet (MHP), respectively. An intermediate type II, clinically corresponding to mild PKU, is characterized by early decline of blood Phe from above 1200 μmol/L down to levels between 600 and 1200 μmol/L at 72 h. Aims: Unbiased classification and kinetic and molecular characterization of the intermediate Phe response; estimation of phenotypic variability of Phe disposal. Method: A kinetic model with zero‐order protein synthesis and first‐order rate of metabolic disposal of Phe is applied to 157 tests. Results: A model of exponentially saturated activation describes the acceleration of Phe disposal from day 1 to 3 in the intermediate type of response. Eleven of 14 p.Y414C functional hemizygotes and two of three p.R261Q homozygotes manifested this kinetic type. The rate estimates of Phe metabolic disposal differ widely in patients with identical PAH genotype, yet are highly correlated with the Phe level at 72 h.
    Type of Medium: Online Resource
    ISSN: 0141-8955 , 1573-2665
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2009
    detail.hit.zdb_id: 2006875-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...